3D bioprinting is a technology where bioinks, mixed with living cells, are printed in 3D to construct natural tissue-like three-dimensional structures. This technology can be used in various research areas, such as tissue engineering and new drug development.
According to this analysis, the Global 3D Bioprinting Market was valued at ~US$ 1 billion in 2017. It is estimated to be ~US$ 2 billion in 2022 and is forecasted to reach a market size of ~US$ 5 billion, growing at a CAGR of ~15% owing to the rising demand from the manufacturing industry.
Several pharmaceutical firms are rapidly utilizing 3D bioprinting goods and technology in process of finding and developing new drugs. Compared to the conventional drug test process, 3D bioprinting allows the drug industry to test medications more affordably and safely, which acts as a driving factor for the growth of the market.
Due to uncontrollable processing parameters and different materials, the additive manufacturing method's accuracy varies between machines. A few monitoring techniques are available to assist producers in fulfilling their unique requirements by correcting these modifications. It has been challenging to create intricate and precise mathematical models using additive manufacturing, which acts as a major challenge for the market.
The market was positively impacted by the COVID-19 pandemic as various 3D Bioprinting communities are responding to the worldwide crises by offering their respective skills to ease the burden on the supply chain and governments. As the cases of COVID-19 are increasing day by day, there has been a shortage of materials for medical professionals as well as for the general public. One of the biggest issues is the lack of availability of test kits for COVID-19. Hence, various 3D bioprinting companies are manufacturing 3D printers and related software on a large scale.
By Material: The living cells segment held the largest market share in the global 3D bioprinting market in 2021, owing to rising demand from the pharmaceutical industry.
Using living cells as bio-inks, the inkjet technology allows for the printing of complex organs and tissues on culture substrates.
Living tissues and organs can be printed in three dimensions by layering living cells. There is growing usage of living cells in regenerative medicine and stem cell research.
By Application: The clinical application segment held the largest market share in the global 3D bioprinting market in 2021, owing to utilization of bioprinting technology in clinical trials of various diseases.
Bioprinting saves time in clinical trials and, thus, is being increasingly used for drug discovery. Biopharmaceutical companies are collaborating with market players to test their drugs.
By Region: North Americaheld the largest market share among all other regions within the global 3D bioprinting market in 2021, due to the supporting government policies to augment the growth of the region.
The increasing incorporation of IT in the healthcare industry and increasing adoption of 3D bioprinting for the production of medical products is expected to be one of the major factors contributing to market growth in this region.
The USA government is spending more on research and development, in order to come up with vaccines for conditions like Covid and other diseases. Due to this reason, there is an increasing demand for 3D bioprinting, as this technology has been reconnoitered for drug testing and organ transplantation.
Country-niche players constitute ~25% of the total number of competitors, while regional players dominate representing ~45% of total competitors. Some of the major players in the market include Organovo Holdings, Inc., Inventia Life Science, Poietis, VIVAX BIO, LLC, CYFUSE BIOMEDICAL K.K., 3D Bioprinting Solutions, CELLINK , BICO - THE BIO CONVERGENCE COMPANY, CollPlant Biotechnologies Ltd., Aspect Biosystems Ltd., among others.
Note: This is an On-Demand/Planned report, so the figures quoted here for market size estimate, forecast, growth, segment share, and competitive landscape are based on initial findings and might vary slightly in the actual report. Also, any required customizations can be covered to the best feasible extent for Pre-booking clients and report delivered within a maximum of 2 working weeks.
This product will be delivered within 5-7 business days.
According to this analysis, the Global 3D Bioprinting Market was valued at ~US$ 1 billion in 2017. It is estimated to be ~US$ 2 billion in 2022 and is forecasted to reach a market size of ~US$ 5 billion, growing at a CAGR of ~15% owing to the rising demand from the manufacturing industry.
Several pharmaceutical firms are rapidly utilizing 3D bioprinting goods and technology in process of finding and developing new drugs. Compared to the conventional drug test process, 3D bioprinting allows the drug industry to test medications more affordably and safely, which acts as a driving factor for the growth of the market.
Due to uncontrollable processing parameters and different materials, the additive manufacturing method's accuracy varies between machines. A few monitoring techniques are available to assist producers in fulfilling their unique requirements by correcting these modifications. It has been challenging to create intricate and precise mathematical models using additive manufacturing, which acts as a major challenge for the market.
The market was positively impacted by the COVID-19 pandemic as various 3D Bioprinting communities are responding to the worldwide crises by offering their respective skills to ease the burden on the supply chain and governments. As the cases of COVID-19 are increasing day by day, there has been a shortage of materials for medical professionals as well as for the general public. One of the biggest issues is the lack of availability of test kits for COVID-19. Hence, various 3D bioprinting companies are manufacturing 3D printers and related software on a large scale.
Scope of the Report
The 3D Bioprinting market is segmented by component, material, application, and region. In addition, the report also covers the market size for each of the four regions' 3D Bioprinting market. The revenue used to size and forecast the market for each segment is US$ billion.Component
- 3D Bioprinters
- Bioinks
Material
- Living Cells
- Hydrogels
- Extracellular Matrices
- Others
Application
- Research Application
- Clinical Application
Region
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
- Asia Pacific (China, Japan, South Korea, India, Indonesia, Australia, Rest of Asia Pacific)
- LAMEA (Latin America, Middle East, Africa)
Key Players
- Organovo Holdings, Inc
- Inventia Life Science
- Poietis
- VIVAX BIO, LLC
- CYFUSE BIOMEDICAL KK
- 3D Bioprinting Solutions
- CELLINK
- BICO - THE BIO CONVERGENCE COMPANY
- CollPlant Biotechnologies Ltd
- Aspect Biosystems Ltd
Key Trends by Market Segment
- By Component: The 3D bioprinters segment held the largest market share in the global 3D bioprinting market in 2021, owing to the growing demand for 3D bioprinting due to the widespread use of pharmaceutical pills to treat a variety of chronic conditions
- Bioprinting is a form of additive manufacturing that uses biomaterials instead of traditional metals and plastics to create 3D tissues
By Material: The living cells segment held the largest market share in the global 3D bioprinting market in 2021, owing to rising demand from the pharmaceutical industry.
Using living cells as bio-inks, the inkjet technology allows for the printing of complex organs and tissues on culture substrates.
Living tissues and organs can be printed in three dimensions by layering living cells. There is growing usage of living cells in regenerative medicine and stem cell research.
By Application: The clinical application segment held the largest market share in the global 3D bioprinting market in 2021, owing to utilization of bioprinting technology in clinical trials of various diseases.
Bioprinting saves time in clinical trials and, thus, is being increasingly used for drug discovery. Biopharmaceutical companies are collaborating with market players to test their drugs.
By Region: North Americaheld the largest market share among all other regions within the global 3D bioprinting market in 2021, due to the supporting government policies to augment the growth of the region.
The increasing incorporation of IT in the healthcare industry and increasing adoption of 3D bioprinting for the production of medical products is expected to be one of the major factors contributing to market growth in this region.
The USA government is spending more on research and development, in order to come up with vaccines for conditions like Covid and other diseases. Due to this reason, there is an increasing demand for 3D bioprinting, as this technology has been reconnoitered for drug testing and organ transplantation.
Competitive Landscape
The Global 3D Bioprinting Market is highly competitive with ~100 players, including globally diversified players, regional players, and many country-niche players. Most of the regional players are the developers of 3D Bioprinting used in various end-user industries.Country-niche players constitute ~25% of the total number of competitors, while regional players dominate representing ~45% of total competitors. Some of the major players in the market include Organovo Holdings, Inc., Inventia Life Science, Poietis, VIVAX BIO, LLC, CYFUSE BIOMEDICAL K.K., 3D Bioprinting Solutions, CELLINK , BICO - THE BIO CONVERGENCE COMPANY, CollPlant Biotechnologies Ltd., Aspect Biosystems Ltd., among others.
Recent Developments Related to Major Players and Organizations
- In March 2022, BICO Company AB, introduced the BIO CELLX, a revolutionary technology that automates 3D cell cultivation processes by utilizing prevalidated procedures
- In May 2021, 3D Systems, a US-based company engaged in offering 3D bioprinting technology announced the acquisition of Allevi Inc Through the acquisition, 3D Systems plans to utilize Allevi’s expertise to develop applications in the future for the development of human organs in the long term and become a market leader in bioprinting
Conclusion
The Global 3D Bioprinting Market witnessed a positive impact due to COVID-19 owing to the growing demand for 3D bioprinters from the healthcare and pharmaceutical industries. 3D bioprinters are the most common component of 3D bioprinting. Majorly, the living cells are used as material in the 3D bioprinting technology for carrying out clinical trials. Though the market is competitive with ~100 participants, regional players control the dominant share in the market and country-niche players also hold a significant share.Note: This is an On-Demand/Planned report, so the figures quoted here for market size estimate, forecast, growth, segment share, and competitive landscape are based on initial findings and might vary slightly in the actual report. Also, any required customizations can be covered to the best feasible extent for Pre-booking clients and report delivered within a maximum of 2 working weeks.
Key Topics Covered in the Report
- Snapshot of Global 3D Bioprinting Market
- Industry Value Chain and Ecosystem Analysis
- Market size and Segmentation of the Global 3D Bioprinting Market
- Historic Growth of Overall Global 3D Bioprinting Market and Segments
- Competition Scenario of the Market and Key Developments of Competitors
- Porter’s 5 Forces Analysis of Global 3D Bioprinting Industry
- Overview, Product Offerings, Strengths, & Weaknesses of Key Competitors
- Covid-19 Impact on the Overall Global 3D Bioprinting Market
- Future Market Forecast and Growth Rates of the Global 3D Bioprinting Market and Segments
- Analysis of Global 3D Bioprinting Market
- Major Production/Supply and Consumption/Demand Hubs within Each Region
- Major Country-wise Historic and Future Market Growth Rates of the Total Market and Segments
- Overview of Notable Emerging Competitor Companies within Each Region
Notable Key Players Mentioned in the Report
- Organovo Holdings, Inc
- Inventia Life Science
- Poietis
- VIVAX BIO, LLC
- CYFUSE BIOMEDICAL KK
- 3D Bioprinting Solutions
- CELLINK
- BICO - THE BIO CONVERGENCE COMPANY
- CollPlant Biotechnologies Ltd
- Aspect Biosystems Ltd
- Organovo
- Prellis Biologics
- Pandorum Technologies
- Regenovo Biotechnology
Key Target Audience - Organizations and Entities Who Can Benefit by Subscribing This Report
- 3D Bioprinting Manufacturers
- 3D Bioprinting Suppliers
- 3D Bioprinters Manufacturers
- Bioinks Manufacturers
- Living Cells Suppliers
- Hydrogels Suppliers
- Extracellular Matrices Suppliers
- 3D Bioprinting Distributors
- Emerging and Startup Companies in 3D Bioprinting
- Different Types of 3D Bioprinting Manufacturing Hubs
- Government Departments of Healthcare
- Government Departments of Pharmaceuticals
- Ministries and Departments of Bio-based Materials
- Importers and Distributors of 3D Bioprinting
Period Captured in the Report
- Historical Period: 2017-2021
- Forecast Period: 2022E-2028F
Frequently Asked Questions
What is the Study Period of this Market Report?- The Global 3D Bioprinting Market is covered from 2017-2028 in this report, which includes a forecast for the period (2022-2028)
- The global 3D Bioprinting market is expected to witness a CAGR of ~15% over the next 6 years
- The high demand for tissues and organs for transplantation is one of the primary drivers for the growth of the global 3D bioprinting market
- The clinical application segment held the largest share of the global 3D bioprinting market in 2021
- Organovo Holdings, Inc., Inventia Life Science, Poietis, VIVAX BIO, LLC, CYFUSE BIOMEDICAL K.K., 3D Bioprinting Solutions, CELLINK, BICO - THE BIO CONVERGENCE COMPANY, CollPlant Biotechnologies Ltd., Aspect Biosystems Ltd., among others are the major companies operating in Global 3D Bioprinting Market
This product will be delivered within 5-7 business days.
Table of Contents
1. Executive Summary
2. Market Overview and Key Trends Impacting Growth
3. Global - Market Segmentation by Component, Historic Growth, Outlook & Forecasts
4. Global - Market Segmentation by Material, Historic Growth, Outlook & Forecasts
5. Global - Market Segmentation by Application, Historic Growth, Outlook & Forecasts
6. Industry/Competition Analysis - Competitive Landscape
7. Key Competitor Profiles (Company Overview, Product Offerings, and Strengths & Weaknesses Analysis)
8. Geographic Analysis & Major Countries Market Historic Growth, Outlook, and Forecasts
9. Industry Expert’s Opinions/Perspectives
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Organovo Holdings, Inc.
- Inventia Life Science
- Poietis
- VIVAX BIO, LLC
- CYFUSE BIOMEDICAL K.K.
- 3D Bioprinting Solutions
- CELLINK
- BICO - THE BIO CONVERGENCE COMPANY
- CollPlant Biotechnologies Ltd.
- Aspect Biosystems Ltd.
- Organovo
- Prellis Biologics
- Pandorum Technologies
- Regenovo Biotechnology
